Free Trial

Pharmaceutical Stocks List

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$133.27
-3.4%
$130.04
$62.55
$170.47
$51.07B1.544.19 million shs3.97 million shs
AbbVie Inc. stock logo
ABBV
AbbVie
$171.35
+1.0%
$163.58
$130.96
$182.89
$302.58B0.65.46 million shs4.25 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$40.82
-0.4%
$44.08
$39.91
$66.38
$82.75B0.4315.48 million shs18.74 million shs
GSK plc stock logo
GSK
GSK
$40.95
+0.7%
$42.55
$33.67
$45.92
$84.87B0.663.57 million shs2.85 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$145.65
-0.2%
$148.13
$143.13
$175.97
$350.53B0.537.36 million shs6.03 million shs
McKesson Co. stock logo
MCK
McKesson
$602.93
+0.9%
$553.85
$395.30
$604.15
$78.37B0.47705,227 shs446,414 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$127.99
+0.4%
$128.66
$99.14
$133.10
$324.17B0.398.02 million shs6.51 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.41
+1.6%
$27.58
$25.20
$39.87
$155.32B0.741.34 million shs29.53 million shs
XPH
SPDR S&P Pharmaceuticals ETF
$39.76
$40.38
$34.67
$45.62
$192.84M0.8737,338 shs37,471 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-3.36%-10.19%+0.28%+29.29%+3.53%
AbbVie Inc. stock logo
ABBV
AbbVie
+0.97%+2.13%+2.96%-2.79%+23.59%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-0.37%-5.16%-7.29%-21.32%-38.30%
GSK plc stock logo
GSK
GSK
+0.69%-0.19%-8.96%-2.36%+16.50%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.22%-0.76%-5.81%-6.49%-11.31%
McKesson Co. stock logo
MCK
McKesson
+0.92%+1.99%+6.80%+13.60%+48.43%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.37%-2.92%-2.44%+3.35%+17.08%
Pfizer Inc. stock logo
PFE
Pfizer
+1.56%-2.25%-4.29%-1.08%-31.58%
XPH
SPDR S&P Pharmaceuticals ETF
0.00%-2.24%-3.43%-7.51%-4.97%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Moderna, Inc. stock logo
MRNA
Moderna
3.6536 of 5 stars
2.13.00.04.63.03.30.6
AbbVie Inc. stock logo
ABBV
AbbVie
4.6475 of 5 stars
2.43.04.23.91.52.52.5
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.7778 of 5 stars
3.13.04.24.02.71.71.9
GSK plc stock logo
GSK
GSK
3.4196 of 5 stars
2.25.03.30.03.40.02.5
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.7403 of 5 stars
3.23.04.23.92.11.71.9
McKesson Co. stock logo
MCK
McKesson
4.8058 of 5 stars
2.45.03.33.02.72.52.5
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.4848 of 5 stars
2.33.03.34.13.21.71.9
Pfizer Inc. stock logo
PFE
Pfizer
4.7692 of 5 stars
3.23.04.24.81.41.71.9
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.24
Hold$129.02-3.19% Downside
AbbVie Inc. stock logo
ABBV
AbbVie
2.86
Moderate Buy$179.644.84% Upside
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$60.0046.99% Upside
GSK plc stock logo
GSK
GSK
2.33
Hold$47.0014.77% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.38
Hold$174.0719.51% Upside
McKesson Co. stock logo
MCK
McKesson
2.87
Moderate Buy$571.47-5.22% Downside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.69
Moderate Buy$133.003.91% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.40
Hold$35.8630.82% Upside
XPH
SPDR S&P Pharmaceuticals ETF
0.00
N/A$66.9968.49% Upside

Current Analyst Ratings

Latest Pharmaceutical Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$185.00 ➝ $190.00
6/18/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$155.00 ➝ $155.00
6/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
6/17/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
6/12/2024
Moderna, Inc. stock logo
MRNA
Moderna
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$163.00 ➝ $179.00
6/5/2024
AbbVie Inc. stock logo
ABBV
AbbVie
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$185.00
6/5/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/4/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
6/4/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$155.00 ➝ $155.00
6/3/2024
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$135.00 ➝ $160.00
6/3/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
(Data available from 6/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$6.85B7.46N/AN/A$36.33 per share3.67
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.57$16.07 per share10.66$5.78 per share29.65
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.01B1.84$12.33 per share3.31$14.49 per share2.82
GSK plc stock logo
GSK
GSK
$37.71B2.25$5.22 per share7.84$7.74 per share5.29
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.12$13.68 per share10.65$28.57 per share5.10
McKesson Co. stock logo
MCK
McKesson
$308.95B0.25$33.55 per share17.97($12.17) per share-49.54
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.39$3.01 per share42.56$14.85 per share8.62
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.66$2.96 per share9.25$15.81 per share1.73
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$15.67N/AN/AN/A-115.82%-20.10%-15.00%8/1/2024 (Estimated)
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$3.3750.8514.182.1611.02%179.47%14.05%7/25/2024 (Estimated)
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B-$3.10N/A5.7913.95-13.50%8.83%2.50%7/26/2024 (Confirmed)
GSK plc stock logo
GSK
GSK
$6.13B$2.7614.849.041.2314.62%51.54%11.01%7/24/2024 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.0813.352.4245.26%36.70%15.07%7/17/2024 (Confirmed)
McKesson Co. stock logo
MCK
McKesson
$3.00B$22.3826.9417.081.380.97%-245.88%5.57%8/7/2024 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.90142.2112.902.503.76%14.05%5.24%7/30/2024 (Confirmed)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B-$0.06N/A9.971.08-0.56%8.64%3.70%8/6/2024 (Estimated)
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/A14.39N/AN/AN/AN/AN/A

Latest Pharmaceutical Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2024N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.14N/A-$2.14N/AN/AN/A  
7/26/2024N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.67N/A-$1.67N/AN/AN/A  
7/17/2024N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.73N/A-$2.73N/AN/AN/A  
5/7/2024Q4 2024
McKesson Co. stock logo
MCK
McKesson
$6.34$6.18-$0.16$6.34$79.32 billion$76.36 billion    
5/3/2024Q1 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.26$2.31+$0.05$3.85$11.93 billion$12.31 billion      
5/2/2024Q1 2024
Moderna, Inc. stock logo
MRNA
Moderna
-$3.59-$3.07+$0.52-$3.07$93.26 million$167.00 million    
5/1/2024Q1 2024
GSK plc stock logo
GSK
GSK
$0.94$1.09+$0.15$1.53$8.98 billion$9.34 billion
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    
4/25/2024Q1 24
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$4.53-$4.40+$0.13$9.69$11.45 billion$11.87 billion      
4/25/2024Q1 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.94$2.07+$0.13$2.27$15.21 billion$15.78 billion    
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.62%+7.84%183.98%52 Years
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.405.88%-0.15%N/A 16 Years
GSK plc stock logo
GSK
GSK
$1.473.59%-18.18%53.26%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.963.41%+5.70%30.92%63 Years
McKesson Co. stock logo
MCK
McKesson
$2.480.41%+11.80%11.08%16 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.41%+6.08%342.22%13 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.13%+2.57%N/A 15 Years
XPH
SPDR S&P Pharmaceuticals ETF
$0.671.69%N/AN/AN/A

Latest Pharmaceutical Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/18/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.605.86%7/5/20248/1/2024
5/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.37623.2%5/16/20245/17/20247/11/2024
5/28/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.772.4%6/17/20246/17/20247/8/2024
4/24/2024
McKesson Co. stock logo
MCK
McKesson
quarterly$0.620.47%6/3/20246/3/20247/1/2024
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
0.04
4.03
3.91
AbbVie Inc. stock logo
ABBV
AbbVie
7.93
0.94
0.83
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.99
1.11
0.99
GSK plc stock logo
GSK
GSK
1.15
0.87
0.58
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.36
1.17
0.94
McKesson Co. stock logo
MCK
McKesson
N/A
0.92
0.51
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.77
1.25
0.99
Pfizer Inc. stock logo
PFE
Pfizer
0.66
1.05
0.78
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
GSK plc stock logo
GSK
GSK
15.74%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
McKesson Co. stock logo
MCK
McKesson
85.07%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
XPH
SPDR S&P Pharmaceuticals ETF
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600383.24 million324.99 millionOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.76 billionOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,1002.03 billion2.03 billionOptionable
GSK plc stock logo
GSK
GSK
70,2002.07 billion1.87 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.40 billionOptionable
McKesson Co. stock logo
MCK
McKesson
51,000129.99 million129.71 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.67 billion5.66 billionOptionable
XPH
SPDR S&P Pharmaceuticals ETF
N/A4.85 millionN/ANot Optionable

Pharmaceutical Stocks Headlines

Recent News About These Companies

SPDR S&P Pharmaceuticals ETF (XPH)
SPDR S&P Pharmaceuticals ETF
XPH ETF Stock Price History
ETF Watch: Fortitude, Not Fashion Wins Out
SPY ETF Gains 11% YTD: Technical Indicators Signal Further Upside

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines

Company Descriptions

Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
McKesson logo

McKesson

NYSE:MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

SPDR S&P Pharmaceuticals ETF

NYSEARCA:XPH
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.
Are you interested in trading pharmaceutical stocks?

Are pharmaceuticals a good potential add-in to your portfolio? Let’s look at how to invest in pharmaceutical companies, step by step.

Learn more about pharmaceutical stocks